241 related articles for article (PubMed ID: 11091129)
1. Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level.
Cotreau MM; von Moltke LL; Beinfeld MC; Greenblatt DJ
J Pharmacol Toxicol Methods; 2000; 43(1):41-54. PubMed ID: 11091129
[TBL] [Abstract][Full Text] [Related]
2. Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen.
Cotreau MM; von Moltke LL; Harmatz JS; Greenblatt DJ
Pharmacology; 2001; 63(4):210-9. PubMed ID: 11729359
[TBL] [Abstract][Full Text] [Related]
3. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
4. Comparative induction of CYP3A and CYP2B in rat liver by 3-benzoylpyridine and metyrapone.
Murray M; Sefton RM; Martini R; Butler AM
Chem Biol Interact; 1998 Jun; 113(3):161-73. PubMed ID: 9717516
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies.
Hamaoka N; Oda Y; Hase I; Asada A
Br J Anaesth; 2001 Apr; 86(4):540-4. PubMed ID: 11573629
[TBL] [Abstract][Full Text] [Related]
6. Rapid determination of rat hepatocyte mRNA induction potential using oligonucleotide probes for CYP1A1, 1A2, 3A and 4A1.
Surry DD; Meneses-Lorente G; Heavens R; Jack A; Evans DC
Xenobiotica; 2000 May; 30(5):441-56. PubMed ID: 10875679
[TBL] [Abstract][Full Text] [Related]
7. Negative regulation by dexamethasone of fluvastatin-inducible CYP2B expression in primary cultures of rat hepatocytes: role of CYP3A.
Kocarek TA; Reddy AB
Biochem Pharmacol; 1998 May; 55(9):1435-43. PubMed ID: 10076536
[TBL] [Abstract][Full Text] [Related]
8. Midazolam is a phenobarbital-like cytochrome p450 inducer in rats.
Hoen PA; Bijsterbosch MK; van Berkel TJ; Vermeulen NP; Commandeur JN
J Pharmacol Exp Ther; 2001 Dec; 299(3):921-7. PubMed ID: 11714877
[TBL] [Abstract][Full Text] [Related]
9. Characterization of rat cytochrome P450 isozymes involved in the covalent binding of cyclosporin A to microsomal proteins.
Sadrieh N; Thomas PE
Toxicol Appl Pharmacol; 1994 Aug; 127(2):222-32. PubMed ID: 8048065
[TBL] [Abstract][Full Text] [Related]
10. Effect of Taxol on cytochrome P450 3A and acetaminophen toxicity in cultured rat hepatocytes: comparison to dexamethasone.
Kostrubsky VE; Lewis LD; Wood SG; Sinclair PR; Wrighton SA; Sinclair JF
Toxicol Appl Pharmacol; 1997 Jan; 142(1):79-86. PubMed ID: 9007036
[TBL] [Abstract][Full Text] [Related]
11. Induction, suppression and inhibition of multiple hepatic cytochrome P450 isozymes in the male rat and bobwhite quail (Colinus virginianus) by ergosterol biosynthesis inhibiting fungicides (EBIFs).
Ronis MJ; Ingelman-Sundberg M; Badger TM
Biochem Pharmacol; 1994 Nov; 48(10):1953-65. PubMed ID: 7986207
[TBL] [Abstract][Full Text] [Related]
12. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):403-13. PubMed ID: 15370957
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
14. Ethylmorphine N-demethylase activity as a marker for cytochrome P450 CYP3A activity in rat hepatic microsomes.
Amacher DE; Schomaker SJ
Toxicol Lett; 1998 Jan; 94(2):115-25. PubMed ID: 9574808
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.
Haaz MC; Rivory L; Riché C; Vernillet L; Robert J
Cancer Res; 1998 Feb; 58(3):468-72. PubMed ID: 9458091
[TBL] [Abstract][Full Text] [Related]
17. In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Takano M
J Pharm Pharmacol; 1999 Apr; 51(4):405-10. PubMed ID: 10385212
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M
J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420
[TBL] [Abstract][Full Text] [Related]
19. Effect of pyrazole and dexamethasone administration on cytochrome P450 2E1 and 3A isoforms in rat liver and kidney: lack of specificity of p-nitrophenol as a substrate of P450 2E1.
Zerilli A; Lucas D; Dreano Y; Picart D; Berthou F
Alcohol Clin Exp Res; 1998 May; 22(3):652-7. PubMed ID: 9622446
[TBL] [Abstract][Full Text] [Related]
20. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers.
Salphati L; Benet LZ
Biochem Pharmacol; 1998 Feb; 55(4):387-95. PubMed ID: 9514072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
